Literature DB >> 12641614

Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia.

G Koliakos1, F Papachristou, A Koussi, V Perifanis, I Tsatra, E Souliou, M Athanasiou.   

Abstract

Renal dysfunction in thalassemia patients can be attributed to chronic anemia, and iron overload as well as to desferioxamine (DFO) toxicity. We analyzed the urine of 91 well-maintained homozygous beta-thalassemia patients, with no evidence of renal disease, for early evidence of kidney dysfunction by means of electrophoresis and quantitative biochemical tests. Measurement of liver magnetic resonance imaging (MRI) T2 values and serum ferritin concentration was used to estimate iron overload. In 55 of the 91 patients, urine analysis indicated signs of tubular dysfunction. The urine concentration of albumin and beta 2-microglobulin, as well as the activity of N-acetyl-beta-D-glucosaminidase (NAG), correlated positively with serum ferritin concentration and liver iron deposition, as detected by MRI T2 values. This suggested that the cause of renal dysfunction in homozygous beta-thalassemia is iron overload. On the other hand, the same urine markers did not correlate with age, indicating that chronic anemia or desferrioxamine (DFO) treatment are not related to renal dysfunction in thalassemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641614     DOI: 10.1046/j.1365-2257.2003.00507.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  24 in total

Review 1.  Renal complications of beta-thalassemia major in children.

Authors:  Ashraf Bakr; Youssef Al-Tonbary; Ghada Osman; Rasha El-Ashry
Journal:  Am J Blood Res       Date:  2014-09-05

2.  GFR in Patients with β-Thalassemia Major.

Authors:  Gai Milo; Revital Feige Gross Nevo; Idit Pazgal; Anat Gafter-Gvili; Ofer Shpilberg; Uzi Gafter; Arie Erman; Pinhas Stark
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-11       Impact factor: 8.237

3.  Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.

Authors:  Laurence Dubourg; Céline Laurain; Bruno Ranchin; Corinne Pondarré; Aoumeur Hadj-Aïssa; Dominique Sigaudo-Roussel; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2012-04-24       Impact factor: 3.714

4.  Renal dysfunction in patients with thalassaemia.

Authors:  Charles T Quinn; Valerie L Johnson; Hae-Young Kim; Felicia Trachtenberg; Maria G Vogiatzi; Janet L Kwiatkowski; Ellis J Neufeld; Ellen Fung; Nancy Oliveri; Melanie Kirby; Patricia J Giardina
Journal:  Br J Haematol       Date:  2011-02-21       Impact factor: 6.998

5.  Early markers of renal dysfunction in patients with beta-thalassemia major.

Authors:  Masoumeh Mohkam; Bibi Shahin Shamsian; Atoosa Gharib; Shahin Nariman; Mohammad T Arzanian
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

6.  Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study.

Authors:  Enas A Hamed; Nagla T ElMelegy
Journal:  Ital J Pediatr       Date:  2010-05-25       Impact factor: 2.638

Review 7.  Iron metabolism in the pathogenesis of iron-induced kidney injury.

Authors:  A M F Martines; R Masereeuw; H Tjalsma; J G Hoenderop; J F M Wetzels; D W Swinkels
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

8.  Renal tubule function in beta-thalassemia after hematopoietic stem cell transplantation.

Authors:  Achra Sumboonnanonda; Kleebsabai Sanpakit; Nuntawan Piyaphanee
Journal:  Pediatr Nephrol       Date:  2008-08-08       Impact factor: 3.714

9.  Frequency of glomerular dysfunction in children with Beta thalassaemia major.

Authors:  Basma A Ali; Ahmed M Mahmoud
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

10.  Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis.

Authors:  Aaron Schein; Cathleen Enriquez; Thomas D Coates; John C Wood
Journal:  J Magn Reson Imaging       Date:  2008-09       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.